Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
HKD 12.66
(0.48%)
HKD 12.66
(0.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.15 Billion CNY | 9.66% |
| 2022 | -2.37 Billion CNY | -462.47% |
| 2021 | -422.77 Million CNY | 72.33% |
| 2020 | -1.52 Billion CNY | -116.74% |
| 2019 | -704.85 Million CNY | -8.56% |
| 2018 | -649.28 Million CNY | -134.13% |
| 2017 | -302.42 Million CNY | -103.04% |
| 2016 | -136.58 Million CNY | -84.64% |
| 2015 | -73.97 Million CNY | -88.08% |
| 2014 | -39.33 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -322.38 Million CNY | -13.17% |
| 2024 Q1 | -316.44 Million CNY | 68.36% |
| 2023 FY | - CNY | 9.66% |
| 2023 Q1 | -602.41 Million CNY | 33.73% |
| 2023 Q3 | -291.31 Million CNY | 45.44% |
| 2023 Q4 | -900.45 Million CNY | -209.1% |
| 2023 Q2 | -533.89 Million CNY | 11.37% |
| 2022 Q3 | -781.23 Million CNY | -32.25% |
| 2022 Q1 | -330.7 Million CNY | -30.09% |
| 2022 FY | - CNY | -462.47% |
| 2022 Q4 | -909.03 Million CNY | -16.36% |
| 2022 Q2 | -590.71 Million CNY | -78.62% |
| 2021 Q3 | -353.73 Million CNY | 15.54% |
| 2021 Q4 | -254.2 Million CNY | 28.14% |
| 2021 Q1 | 502.96 Million CNY | 187.92% |
| 2021 Q2 | -418.8 Million CNY | -183.27% |
| 2021 FY | - CNY | 72.33% |
| 2020 Q2 | -365.71 Million CNY | -79.97% |
| 2020 FY | - CNY | -116.74% |
| 2020 Q4 | -572.08 Million CNY | -17.92% |
| 2020 Q3 | -485.14 Million CNY | -32.66% |
| 2020 Q1 | -203.2 Million CNY | 32.27% |
| 2019 Q1 | -199.8 Million CNY | 21.58% |
| 2019 Q4 | -300.03 Million CNY | -63.66% |
| 2019 Q3 | -183.32 Million CNY | -108.19% |
| 2019 Q2 | -88.05 Million CNY | 55.93% |
| 2019 FY | - CNY | -8.56% |
| 2018 Q1 | -87.68 Million CNY | 29.51% |
| 2018 Q3 | -151.03 Million CNY | 8.98% |
| 2018 FY | - CNY | -134.13% |
| 2018 Q2 | -165.93 Million CNY | -89.24% |
| 2018 Q4 | -254.8 Million CNY | -68.7% |
| 2017 FY | - CNY | -103.04% |
| 2017 Q3 | -70.22 Million CNY | -0.71% |
| 2017 Q4 | -124.4 Million CNY | -77.14% |
| 2017 Q2 | -69.73 Million CNY | -0.42% |
| 2017 Q1 | -69.43 Million CNY | -32.7% |
| 2016 FY | - CNY | -84.64% |
| 2016 Q1 | -23.78 Million CNY | 8.39% |
| 2016 Q4 | -52.32 Million CNY | 2.19% |
| 2016 Q3 | -53.49 Million CNY | -124.89% |
| 2016 Q2 | -23.78 Million CNY | 0.0% |
| 2015 Q4 | -25.96 Million CNY | 0.0% |
| 2015 Q2 | -11.02 Million CNY | 0.0% |
| 2015 Q1 | -11.02 Million CNY | 18.09% |
| 2015 FY | - CNY | -88.08% |
| 2015 Q3 | -25.96 Million CNY | -135.59% |
| 2014 Q3 | -13.45 Million CNY | -116.67% |
| 2014 FY | - CNY | 0.0% |
| 2014 Q2 | -6.21 Million CNY | 0.0% |
| 2014 Q1 | -6.21 Million CNY | 0.0% |
| 2014 Q4 | -13.45 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 2464.975% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 543.237% |